Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the ...
Researchers decipher the function of an ion channel involved in cellular degradation processes and create new possibilities for Parkinson’s therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback